Unsafe
Not Aligned
Patient Risk:
High
Summary
None of the provided statements are supported by the supplied prescribing information excerpts. All claims relate to diabetes insipidus or formulation/brand availability and are not addressed in the provided label text, so they are unsupported by the excerpted FDA labeling.
Category Scores
Accurate Statements
Unsupported Statements
Vasopressin is an antidiuretic hormone used for central diabetes insipidus.
The provided label excerpt for INDICATIONS AND USAGE is for increasing blood pressure in adults with vasodilatory shock; no indication for central diabetes insipidus is provided in the supplied text.
Vasopressin is often more commonly available as an injectable medicine rather than as tablets in many markets.
The provided label excerpts do not include formulation/market availability or tablet vs injection statements.
Some vasopressin products may be injections rather than tablets.
The provided label excerpts do not discuss dosage forms across products or tablet vs injection availability.
Pitressin is a common global brand name for vasopressin.
The provided label excerpts do not mention brand names such as Pitressin or any statements about global branding.
Pitressin is often associated with injection formulations.
The provided label excerpts do not mention Pitressin or any relationship to injection formulations.
Contradictions
Important Omissions
If discussing vasopressin, the label excerpt indicates an approved indication for vasodilatory shock with hypotension despite fluids/catecholamines; the statements instead describe central diabetes insipidus and do not address the FDA-approved indication from the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Unsupported indication claims (central diabetes insipidus) could mislead clinical use. Formulation/brand availability claims are also unsupported by the provided prescribing information excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Statements are not supported by the provided FDA label excerpts, especially the indication claim for central diabetes insipidus and brand/formulation statements (Pitressin, injections vs tablets).
Suggested Improvement
Limit claims to what is supported by the supplied label excerpts (e.g., the provided FDA-approved indication for vasodilatory shock; dosing/titration; contraindication; and label-listed precautions). Remove or rework unsupported claims about central diabetes insipidus, Pitressin branding, and formulation availability unless supported by included label text.